Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this prospective, open-label, pairing design, single-center study is to
evaluate the effect of individualized rATG dosing vs traditional weight-based rATG dosing
regimen（10mg/kg）for patients with acute leukemia undergoing a myeloablative conditioning
regimen and haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University